PlaqueTec appoints Dr Nick West as CMO
pharmafile | November 24, 2015 | Appointment | Research and Development | PlaqueTec
PlaqueTec has appointed Dr Nick West as its new chief medical officer.
Dr West is a research-active clinician with extensive clinical trial experience in both industry-sponsored and investigator-initiated studies, with extensive track record of publication in intravascular imaging, coronary physiology and novel medical devices, including bioabsorbable stents.
He is also a consultant interventional cardiologist at Papworth Hospital in Cambridge. He graduated in medicine from the University of Cambridge and undertook his cardiology training at the John Radcliffe Hospital in Oxford. He previously undertook research towards his doctoral thesis in the field of endothelial biology at both the University of Oxford and Duke University, North Carolina.
Dr West has previously been clinical lead for interventional cardiology at Papworth, deputy chair of the British Cardiovascular Society acute cardiac care working group and a longstanding member of the guidelines and clinical practice committee. He has also acted as an expert advisor to NICE, peer-reviews for journals and is a faculty member at national and international cardiology meetings.
Dr West says: “I am excited about joining the PlaqueTec management team. The company has developed a pioneering technology and the latest clinical study demonstrates that its approach significantly improves the resolution of coronary disease biomarkers. Preliminary data suggests that PlaqueTec’s technology has the potential to greatly benefit the development of new CAD therapies.”
Dr West has consulted with PlaqueTec for a number of years as medical advisor, and was principal investigator for both PlaqueTec’s recent clinical study and the first-in-man study that preceded it.
